We are live on ! Find out more
CYTK icon

Cytokinetics
CYTK

380 hedge funds and large institutions have $7.75B invested in Cytokinetics in 2025 Q3 according to their latest regulatory filings, with 101 funds opening new positions, 126 increasing their positions, 102 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

312% more call options, than puts

Call options by funds: $361M | Put options by funds: $87.6M

288% more first-time investments, than exits

New positions opened: 101 | Existing positions closed: 26

70% more capital invested

Capital invested by funds: $4.55B → $7.75B (+$3.2B)

33% more funds holding in top 10

Funds holding in top 10: 12 → 16 (+4)

24% more repeat investments, than reductions

Existing positions increased: 126 | Existing positions reduced: 102

22% more funds holding

Funds holding: 311 → 380 (+69)

2.5% more ownership

Funds ownership: 115.28% → 117.77% (+2.5%)

Holders
380
Holders Change
+69
Holders Change %
+22.19%
% of All Funds
4.99%
Holding in Top 10
16
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+33.33%
% of All Funds
0.21%
New
101
Increased
126
Reduced
102
Closed
26
Calls
$361M
Puts
$87.6M
Net Calls
+$273M
Net Calls Change
+$103M

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$75.1M
2
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$60.9M
3
WP
Woodline Partners
California
+$59.1M
4
DTC
Deep Track Capital
Connecticut
+$26.8M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$20.6M

Top Sellers

1
VPC
Vestal Point Capital
New York
-$92.7M
2
UBS Group
UBS Group
Switzerland
-$52.2M
3
AllianceBernstein
AllianceBernstein
Tennessee
-$47.4M
4
O
OrbiMed
New York
-$35.6M
5
State Street
State Street
Massachusetts
-$31.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
T. Rowe Price Investment Management
1
T. Rowe Price Investment Management
Maryland
$1.05B +$60.9M +1,478,056 +8%
BlackRock
2
BlackRock
New York
$853M -$6.27M -152,120 -1%
Fidelity Investments
3
Fidelity Investments
Massachusetts
$720M +$75.1M +1,824,136 +16%
Vanguard Group
4
Vanguard Group
Pennsylvania
$652M -$5.23M -127,043 -1%
Wellington Management Group
5
Wellington Management Group
Massachusetts
$407M -$17.3M -419,118 -5%
State Street
6
State Street
Massachusetts
$309M -$31.1M -755,419 -12%
DTC
7
Deep Track Capital
Connecticut
$236M +$26.8M +650,000 +18%
Bank of America
8
Bank of America
North Carolina
$168M +$17.1M +416,228 +16%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$167M +$1.89M +45,757 +2%
PCH
10
Polar Capital Holdings
United Kingdom
$153M -$637K -15,471 -0.6%
RI
11
RTW Investments
New York
$150M – – –
T. Rowe Price Associates
12
T. Rowe Price Associates
Maryland
$130M +$20.6M +500,871 +27%
UBS Group
13
UBS Group
Switzerland
$99.1M -$52.2M -1,267,414 -41%
WP
14
Woodline Partners
California
$90.6M +$59.1M +1,435,422 +676%
Goldman Sachs
15
Goldman Sachs
New York
$89.8M +$14.9M +360,740 +28%
JP Morgan Chase
16
JP Morgan Chase
New York
$84.8M +$9.29M +225,443 +17%
Morgan Stanley
17
Morgan Stanley
New York
$83.6M +$16.6M +403,106 +36%
Northern Trust
18
Northern Trust
Illinois
$77.3M +$1.14M +27,641 +2%
IHAM
19
Integral Health Asset Management
New York
$76.9M +$16.5M +400,000 +40%
Citadel Advisors
20
Citadel Advisors
Florida
$76.2M +$3.6M +87,456 +7%
Charles Schwab
21
Charles Schwab
California
$75.5M +$691K +16,766 +1%
AC
22
Armistice Capital
New York
$65.8M -$4.76M -115,481 -9%
NNPTE
23
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne
Poland
$65.5M +$4.53M +109,921 +10%
Capital International Investors
24
Capital International Investors
California
$64.8M +$440K +10,670 +0.9%
Principal Financial Group
25
Principal Financial Group
Iowa
$64.5M -$427K -10,357 -0.9%
1
2 3 4 5

CYTK Hedge Fund Activity: Q3 2025 in Review

380 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q3 2025, worth a combined $7.75B — up 70% from $4.55B a quarter earlier.

Buyers outnumbered sellers: 101 funds opened new CYTK positions and 26 closed out — a net gain of 75 holders — while 126 added to existing stakes and 102 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $75.1M. The largest seller was Vestal Point Capital, cutting an estimated $92.7M.

  • 380 institutional investors held Cytokinetics (CYTK) as of Q3 2025, up from 311 in Q2 2025.
  • Funds reported $7.75B of Cytokinetics stock for Q3 2025, up 70% quarter-over-quarter.
  • 101 funds opened new Cytokinetics positions in Q3 2025 and 26 closed out, a net change of +75 holders.
  • The largest Cytokinetics buyer in Q3 2025 was Fidelity Investments, an estimated $75.1M added.
  • The largest Cytokinetics seller in Q3 2025 was Vestal Point Capital, an estimated $92.7M sold.

Based on aggregated 13F filings for Q3 2025.